|Slideshows|August 10, 2018

5 Reports on Depression

This special collection provides new insights on major aspects of depression: psychopharmacology, therapeutic interventions, major depressive episodes, biomarkers, and pseudobulbar affect.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

Managing Treatment-Resistant Depression: Insights From David Medina, MD, FAPA

ByDavid Medina, MD, FAPA

December 2nd 2025

Looking Back: Key Insights from November 2025

ByJessica Walters

November 28th 2025

FDA Clears Investigational New Drug Application for TNX-102 SL for Treatment of Major Depressive Disorder

ByJessica Walters

November 24th 2025

transcranial magnetic stimulation depression treatment

Use of TMS in Treatment of Depression, Discussion With Rachel Rohaidy, MD

ByRachel Rohaidy, MD

November 24th 2025

Glutamatergic Pathways in Major Depressive Disorder: Insights From Juan D. Oms, MD, FAPA

ByJuan D. Oms, MD, FAPA

November 22nd 2025

Latest CME

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

5 Reports on Depression

Newsletter

Related Content

Managing Treatment-Resistant Depression: Insights From David Medina, MD, FAPA

Looking Back: Key Insights from November 2025

FDA Clears Investigational New Drug Application for TNX-102 SL for Treatment of Major Depressive Disorder

Use of TMS in Treatment of Depression, Discussion With Rachel Rohaidy, MD

Glutamatergic Pathways in Major Depressive Disorder: Insights From Juan D. Oms, MD, FAPA

Latest CME

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Psychedelic PSX-001 for Generalized Anxiety Disorder: A Conversation With Lou Barbato, MD

Antidepressants Assessed for Reducing Negative Symptoms of Schizophrenia

The Concept of Mental Illness, and Why the DSM Approach Is Wrong

Favorable Profile Data On MK-2214 for Treatment of Alzheimer Disease

Antidotes to Fear of Death